KCP-506 / Roche, TuHURA Bio - LARVOL DELTA

Kineta Announces Patent Issuance for U.S. Patent Covering Composition of Matter of KCP506, a Novel Non-opioid Therapy for Chronic Pain (PRNewswire) - "Kineta...announced today that the company has received Patent No. 11,014,970 for Modifications and Uses of Conotoxin Peptides from the U.S. Patent and Trademark Office ('USPTO') related to KCP506, the company's novel non-opioid therapy in development to treat chronic neuropathic pain....A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted from an application. The patent will have a term that expires no earlier than 2035."

Patent • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 (PRNewswire) - "Kineta...announced today that the first participant has been successfully dosed in a Phase 1 multiple ascending dose (MAD) clinical trial of KCP506, an investigational, first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain....The trial is designed to enroll up to 24 participants with safety, tolerability and pharmacokinetic data expected to read out in the second half of 2021."

P1 data • Trial status • CNS Disorders • Neuralgia • Pain

Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain (PRNewswire) - "Kineta Inc...announced today that the first participant has been successfully dosed in a Phase 1 clinical trial of KCP506, an investigational, first-in-class α9/α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain....The Phase 1, first-in-human, double blinded, placebo controlled, single ascending and multiple ascending dose study is designed to evaluate the safety, tolerability, and pharmacokinetics of KCP506 in healthy people. The trial is designed to enroll up to 88 participants with safety, tolerability and pharmacokinetic data expected to read out in the second half of 2021."

P1 data • Trial status • CNS Disorders • Neuralgia • Pain

Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid (PRNewswire) - "Kineta Chronic Pain...announced today that the company will extend and expand its research collaboration with Genentech...With the extension, Kineta will continue development of α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists and will advance KCP506 through Phase 1 clinical trials....Kineta recently received Clinical Trial Application (CTA) approval from the Netherlands to initiate Phase 1 trials of KCP506. A single ascending dose and multiple ascending dose study will be conducted in healthy subjects to evaluate the safety, tolerability, and pharmacokinetics of KCP506 and will commence in Q4 2020."

Licensing / partnership • Trial initiation date • CNS Disorders • Neuralgia • Pain